Table 2.
HSP70-based therapies in cancer clinical trials and case studies.
| HSP70-Based Therapies | Condition | Clinical Trial Phase/Case Study | Refs. |
|---|---|---|---|
| Autologous HSP70-peptide complex in combination with imatinib mesylate | Chronic myeloid leukemia | Phase I | [247] |
| Autologous HSP70-peptide complex (AG-858) in combination with Gleevec | Chronic Myelogenous Leukemia | Phase II | [248] |
| Autologous peripheral blood mononuclear cells (PBMC) pre-activated with TKD peptide/IL-2 | Colon carcinoma | Case study | [242] |
| Autologous NK cells pre-activated with TKD and IL-2 following radiochemotherapy | Advanced colorectal carcinoma and non- small cell lung carcinoma (NSCLC) | Phase I; Phase II | [124,243] |
| DNA vaccine expressing HPV16 E7 mutant form and HSP70 | Cervical intraepithelial neoplasia | Phase I | [244] |
| Dendritic cells transfected with HSP70 mRNA | Hepatocellular carcinoma | Phase I | [245] |
| Autologous NK cells pre-treated with TKD/IL-2 in combination with radiochemotherapy and nivolumab (PD-1 antibody) | NSCLC stage IIIb | Case study | [246] |
| Intratumoral injection of recombinant oncolytic type 2 adenovirus overexpressing HSP70 (H103) | Advanced solid tumors | Phase I | [249] |